Relapse/Recurrence Prevention in Major Depressive Disorder: 26-Month Follow-Up of Mindfulness-Based Cognitive Therapy Versus an Active Control

Amanda J. Shallcross
New York University School of Medicine

Emily C. Willroth
Aaron Fisher
University of California, Berkeley

Sona Dimidjian
University of Colorado, Boulder

James J. Gross
Stanford University

Pallavi D. Visvanathan
Manhattan Mindfulness-Based Cognitive Behavioral Therapy

Iris B. Mauss
University of California, Berkeley

We conducted a 26-month follow-up of a previously reported 12-month study that compared mindfulness-based cognitive therapy (MBCT) to a rigorous active control condition (ACC) for depressive relapse/recurrence prevention and improvements in depressive symptoms and life satisfaction. Participants in remission from major depression were randomized to an 8-week MBCT group (n = 46) or the ACC (n = 46). Outcomes were assessed at baseline; postintervention; and 6, 12, and 26 months. Intention-to-treat analyses indicated no differences between groups for any outcome over the 26-month follow-up. Time to relapse results (MBCT vs. ACC) indicated a hazard ratio = .82, 95% CI [.34, 1.99]. Relapse rates were 47.8% for MBCT and 50.0% for ACC. Piecewise analyses indicated that steeper declines in depressive symptoms in the MBCT vs. the ACC group from postintervention to 12 months were not maintained after 12 months. Both groups experienced a marginally significant rebound of depressive symptoms after 12 months but were still improved at 26 months compared to baseline (b = –4.12, p <= .008). Results for life satisfaction were similar. In sum, over a 26-month follow-up, MBCT was no more effective for preventing depression relapse/recurrence, reducing depressive symptoms, or improving life satisfaction than a rigorous ACC. Based on epidemiological data and evidence from prior depression prevention trials, we discuss the possibility that both MBCT and ACC confer equal therapeutic benefit. Future studies that include treatment as usual (TAU) control conditions are needed to confirm this possibility and to rule out the potential role of time-related effects. Overall findings
underscore the importance of comparing MBCT to TAU as well as to ACCs.

**Keywords:** mindfulness-based cognitive therapy; depression relapse/recurrence prevention; depressive symptoms; active control condition; long-term follow-up

**Major Depressive Disorder (MDD)** is a leading cause of disability worldwide (Ferrari et al., 2013). The 50–80% rate of depression relapse (Judd, 1997) has prompted a focus on treatments aimed at preventing relapse/recurrence. Mindfulness-based cognitive therapy (MBCT) has been shown to reduce depression relapse/recurrence compared with usual care (Ma & Teasdale, 2004; Teasdale, Williams, Ridgeway, Soulsby, & Lau, 2000) in individuals with three or more episodes of MDD. Further, three randomized controlled trials (RCTs) have shown MBCT combined with support to taper or discontinue antidepressant medications (ADM) as is as effective as maintenance ADM (mADM) for reducing risk of relapse/recurrence (Kuyken et al., 2008, 2015, 2016; Segal, Martin, & Joseph, 2010). One recent inferiority trial, however, demonstrated that MBCT following discontinuation of ADM was not superior to mADM (Huijbers et al., 2016). While it is unclear whether MBCT is a viable alternative to mADM, meta-analyses support that it is an efficacious intervention for depressive relapse/recurrence prevention, relative to treatment as usual (TAU) and mADM (Kuyken et al., 2016; Piet & Hougard, 2011).

Despite this research supporting the benefits of MBCT, three gaps in the evidence for MBCT warrant further attention. First, little is known about the effects of MBCT compared to psychoeducational active control conditions (ACCs). Comparing MBCT to rigorous ACCs is important because MBCT is not yet widely available and other psychoeducational interventions may produce similar benefits with cost, acceptability, accessibility, and dissemination advantages (Parikh et al., 2012). Second, to understand the active ingredients of MBCT, it is necessary to compare it to structurally equivalent and therapeutically credible ACCs that are matched to MBCT on nonspecific therapeutic factors but that lack mindfulness and cognitive therapy components. This is important because although mindfulness and cognitive therapy are widely assumed to be the components of MBCT that are responsible for its effects (Williams et al., 2014), nonspecific factors such as amount of group contact, treatment-related activity outside of class, interaction with a facilitator, therapeutic allegiance and alliance, emphasis on self-monitoring and behavior change, perceived social support, and expected positive outcomes have each been shown to contribute to psychological treatment outcomes (Huijbers & Cuijpers, 2014; Wampold, 2015). Further, some of these variables may account for more of the variance in outcomes than specific psychoeducational treatment approaches (Chatoire & Kurpnick, 2001). Third, the longer-term effects (i.e., greater than 12 months) of MBCT versus ACCs are poorly understood. Longer-term follow-up of depression outcomes is critical because depression follows a chronic and recurrent course (Bockting, Hollon, Jarrett, Kuyken, & Dobson, 2015). Extended follow-up studies of psychosocial treatments, in particular, are needed to understand the trajectory and duration of effects and which treatments are most appropriate for the prevention of depressive relapse/recurrence over the longer term.

The broader literature on mindfulness-based interventions (MBIs) includes a range of studies that have compared MBIs to ACCs. However, the MBIs, ACCs, and the samples in these studies do not sufficiently overlap with our investigation to be included in our focused literature review. Thus, we focus on MBCT versus ACC studies in participants with a history of recurrent MDD.

Only a handful of studies have compared MBCT to ACCs. Evidence for the efficacy of MBCT compared to an ACC is supported by at least one RCT that found MBCT to be superior to a psychoeducational control condition for reducing depressive symptoms over a 26-week follow-up (Chiesa et al., 2015). We are aware of only two RCTs that have compared MBCT to an ACC for the prevention of depression relapse/recurrence (Meadows et al., 2014; Williams et al., 2014). Neither study found MBCT to be superior to an ACC for extending time to relapse/recurrence except in subgroups of participants. For example, Meadows et al. (2014) found that MBCT was associated with an extended time to relapse/recurrence in participants who attended four or more sessions and who received specialized care or pharmacological treatment. In the Williams et al. (2014) study, time to relapse/recurrence was extended in individuals who had a history of childhood trauma. Despite evidence supporting that certain types of individuals may benefit more from MBCT versus a psychoeducational ACC, the specificity, active ingredients, and longer-term effects of MBCT remain unclear for two reasons.

First, the respective ACCs in each of these studies did not control for the range of nonspecific psychological components that may impart therapeutic benefit. For example, the ACC in the Meadows et al. (2014) trial was developed primarily to reduce the discrepancy between groups in
treatment expectation. Thus, their “depression relapse active monitoring” (DRAM) control condition, which included a brief training in self-monitoring during the intake assessment interview, was not matched to MBCT on amount of group contact, treatment-related activity outside of class (i.e., home-based practice), interaction with a facilitator, therapeutic allegiance and alliance, and perceived social support. Although considerably more comprehensive in terms of matching on the range of plausible nonspecific therapeutic ingredients, the ACC in the Williams et al. (2014) study, a “cognitive psychological education” control group, did not include equivalent home-based practice. Thus, the active ingredients of MBCT cannot be clearly determined from these investigations because neither of them included control conditions that were matched to MBCT on the most comprehensive range of therapeutically probable nonspecific components—namely, amount of group contact, treatment-related activity outside of class, interaction with a facilitator, therapeutic allegiance and alliance, emphasis on self-monitoring and behavior change, perceived social support, and expected positive outcomes.

Second, of these two studies, only the Meadows et al. (2014) trial examined effects beyond 12 months. Although this investigation found no group differences for extending time to relapse/recurrence, results indicated that fewer MBCT versus ACC participants experienced a relapse over a 24-month follow-up. These findings support the possibility that effects of MBCT versus an ACC may emerge after a longer follow-up period (e.g., beyond 12 months) and substantiate the need for longer-term investigations of MBCT versus ACCs for depression relapse prevention (Bockting et al., 2015).

We conducted a 12-month study to compare MBCT to a structurally equivalent and validated ACC that was matched to MBCT on a comprehensive range of nonspecific factors (amount of group contact, treatment-related activity outside of class, interaction with a facilitator, therapeutic allegiance and alliance, emphasis on self-monitoring and behavior change, perceived social support, and expected positive outcomes) that have been shown in prior studies to contribute to depression outcomes (Huibers & Cuijpers, 2014; Parsons, Crane, Parsons, Fjorback, & Kuyken, 2017; Wampold, 2015) but have not been included in prior efficacy trials of MBCT. Results from this study indicated no differences between groups for depressive relapse/recurrence rates, time to relapse/recurrence, or levels of depressive symptoms and life satisfaction (Shallcross et al., 2015).

Although relapse outcomes and levels of depressive symptoms were not different between groups, the trajectory of depressive symptom improvement did vary by group. As reported in Shallcross et al. (2015), analyses indicated a significant Group × Quadratic Time interaction such that the ACC experienced immediate symptom reduction, which was followed by a gradual increase in symptoms over the 12-month follow-up. In contrast, the MBCT group experienced continued reductions in depressive symptoms (with no increase) over the 12-month follow-up. This finding could be explained by differential rates of therapeutic benefit associated with intervention-specific skills acquisition.

For example, the knowledge and skill focus of the ACC, which included physical activity, functional movement, nutrition, and music therapy, may lead to more immediate reductions in depressive symptoms through distraction, improved self-efficacy, or neurohormonal mechanisms (e.g., increases in serotonin, dopamine; Craft & Perna, 2004; Maratos, Crawford, & Procter, 2011; Opie, O’Neil, Itsiopoulos, & Jacka, 2015). These effects, however, might not be sustained over the longer term. On the other hand, the neurocognitive improvements in attention regulation and self-referential processing that are associated with mindfulness meditation (Chiesa & Serretti, 2011; Goldin, Ziv, Jazaieri, & Gross, 2012) might lead to more gradual (Grossman, Niemann, Schmidt, & Walach, 2004) but cumulative and sustained reductions in depressive symptoms.

Theory and evidence supporting the benefits of MBCT for reducing key cognitive vulnerability factors associated with depressive relapse (e.g., rumination and cognitive reactivity) (Michalak, Holz, & Teismann, 2011) suggest that differences between groups may emerge after 12 months. This idea is consistent with a study showing long-term and significant reductions in depressive symptoms in MBCT versus TAU over a 56-week follow-up (Godfrin & van Heeringen, 2010). Additionally, two single-arm trials have shown sustained reductions in depressive symptoms after MBCT training. One study demonstrated reductions in symptoms for 34 months (Mathew, Whitford, Kenny, & Denson, 2010) and another showed sustained reductions for 58.9 months (Munshi, Eisendrath, & Delucchi, 2013).

This evidence supports the possibility that the downward trajectory of depressive symptoms from postintervention to 12 months may continue in the MBCT group, and these reductions could translate to an emergent effect of MBCT versus ACC for depression relapse/recurrence rates over an extended follow-up period. An equally likely possibility,
however, is that in the absence of supportive or supplementary treatment beyond the 8-week intervention, depressive symptoms may level off or increase in the MBCT group after 12 months, thus mimicking the trajectory of increasing symptoms in the ACC group. In sum, these considerations raise the question of whether MBCT would show significant advantage over the ACC at follow-up assessments past 12 months.

The present study examined this question by extending our earlier investigation and comparing MBCT with an ACC over a total follow-up period of 26 months. Outcomes include depression relapse/recurrence rates, time to relapse/recurrence, depressive symptoms, and life satisfaction. To examine whether subgroups of participants may benefit differentially from MBCT versus ACC, we also conducted exploratory analyses of several theoretically and empirically supported moderators that include age of onset of depression, baseline levels of depressive symptoms and life satisfaction, ADM use, sex, intervention dose, and self-reported practice. Each one of these moderators was tested in our original 12-month follow-up trial (Shallcross et al., 2015) and was selected because it had been shown in prior studies to be associated with depression outcomes or to moderate effects of MBCT (Braun, Gregor, & Tran, 2013; Kuyken et al., 2016; Parsons et al., 2017).

Method

STUDY DESIGN AND PARTICIPANTS

Complete details of the method are described in our original investigation (Shallcross et al., 2015). The study design was a randomized, single-blind, 8-week parallel comparison of MBCT (n = 46) and a validated ACC (n = 46). Consent and IRB approval were obtained. Eligibility was assessed via a combination of an online screening assessment and an in-person assessment using the Structured Clinical Interview for the DSM-IV (SCID-IV; First, Spitzer, Gibbon, & Williams, 2002).

MEASURES

The primary outcomes were depressive relapse/recurrence rates and time to relapse/recurrence, defined as meeting relevant SCID criteria for MDD for at least 2 weeks. Relapse/recurrence was assessed at 6, 12, and 26 months postintervention and covered the full duration of time since the prior interview. Clinical interviews at 6 and 12 months were conducted by two fifth-year doctoral trainees in psychology. Reliability between interviewers for the diagnosis of a depressive episode yielded an average kappa coefficient of .84 based on the 6- and 12-month interviews. Only one of the two interviewers was available to conduct the 26-month
assessment. Thus, assessment of reliability at this time point was not possible. In support of the diagnostic validity of the 26-month assessment, the remaining interviewer was an advanced Ph.D.-level clinical psychology student (who received her Ph.D. during the study period) and who had extensive training in clinical psychological assessment, including 7 years of experience conducting SCID interviews for this and other clinical trials. She additionally achieved high reliability with the interviewer at the 6- and 12-month clinical assessments (kappa = .84).

Blinding of the interviewers over the entire study period with regard to study hypotheses and participant group assignment was maintained via several methods. First, neither interviewer was part of the core research team. Thus, interviewers were not involved with study-related discussions and did not have access to data or results from the initial trial, which were published after the final 26-month interview. Second, interviewers followed a standardized script, which included an explicit reminder to participants at the beginning of each interview not to reveal information about their group assignment. Finally, interviewers were supervised by an experienced research clinician who was also blind to group assignment. As a part of this supervision, the importance of remaining blind was emphasized. One incident of unintentional unblinding at the 12-month follow-up was reported. The audiotape for this interview was edited to remove the segment where group assignment was inadvertently revealed. The edited audio was evaluated by the second interviewer who made the final diagnosis.

Additional outcomes included depressive symptoms and life satisfaction assessed at baseline; postintervention; and at 6, 12, and 26 months measured with self-report questionnaires (i.e., the BDI-II; Beck, Steer, & Brown, 1996) and the Satisfaction With Life Scale (SWL; Diener, Emmons, Larsen, & Griffin, 1985), respectively. Internal consistency for all BDI-II and SWL assessments was $\alpha > .85$.

Putative moderator variables included age of onset of depression (assessed via SCID-IV), baseline depressive symptoms, life satisfaction, and ADM use (assessed via self-report); sex; per-protocol completion (based on attendance of four or more classes); self-report of total practice time outside of class during intervention (sum of minutes of practice logged during the 8-week intervention); and self-report of total practice time since the intervention (sum of retrospective estimation of number of minutes of practice each week assessed at 6, 12, and 24 months).

**DATA ANALYTIC STRATEGY**

**Depressive Relapse/Recurrence and Time to Relapse/Recurrence**

Fisher’s exact test was used to compare the proportions of depressive relapse/recurrence between groups. Cox proportional hazards were used to estimate survival curves. Participants with missing data and those who did not experience a relapse/recurrence were treated as censored observations. Primary outcomes were analyzed separately for intention-to-treat (ITT) and per-protocol (PP) samples. The PP sample included participants who received the minimum effective dose of MBCT (four or more sessions; Teasdale et al., 2000) or an equivalent dose of ACC.

**Depressive Symptoms and Satisfaction With Life**

Full information maximum likelihood (FIML) mixed-effects regression models were used to analyze depressive symptoms and life satisfaction across time between groups. Models were based on a piecewise analysis of time, which allow for the representation of multiple discrete time periods by modeling separate variables (and therefore separate coefficients and slopes) for these periods. Using this approach, the original follow-up period (reported in our original investigation) and the extended follow-up period can be conceptualized as discrete and yet represented within the same model. This allowed us to test for emergent benefits during the extended follow-up period while controlling for effects during the original follow-up period. Piece 1 was the period from pretreatment to posttreatment, Piece 2 was the original follow-up period from posttreatment to 12 months, and Piece 3 was the extended follow-up from 12 to 26 months. Time was mean centered in all analyses.

We followed an iterative process to build the mixed-effects models predicting change in depressive symptoms and satisfaction with life over time. First, the random effects of each piece (i.e., time period) were added sequentially, and statistically significant ($p < .05$) effects were retained. Next, fixed effects of group, piece, and all Group × Piece interactions were added to the model. Interaction terms were retained when statistically significant.

**Missing Data**

Attrition rates and PP completion did not differ between groups at any time point. Comparisons of outcomes between PP completers versus noncompleters and comparisons between participants with present versus missing data in the PP and ITT samples were conducted to assess whether data were missing at random. For PP completers versus noncompleters, no differences emerged in any outcome variable ($p > .15$). For PP completers...
with present versus missing data, participants with missing data had lower incidence of relapse/recurrence at 26 months ($p = .023$). In the ITT sample, participants with missing data had lower baseline depressive symptoms ($p = .013$) and lower incidence of relapse/recurrence at 26 months ($p = .012$). Because data were not missing completely at random, we used pattern-mixture models (Tasca & Gallop, 2009) to test whether effects on time to relapse/recurrence and depressive symptoms were independent of missing data patterns.

Cox proportional hazards were used to estimate survival curves for time to relapse/recurrence as a function of missing data patterns. Participants with missing data were compared to participants with no missing data during the 26-month follow-up period (Pattern 1). There were no group differences in missing data patterns for the PP or ITT samples ($ps > .41$). There was a marginally significant main effect of Pattern 1 on time to relapse/recurrence for the ITT sample only ($p = .08$). Thus, Pattern 1 was entered as a covariate into Cox proportional hazards models to control for the effect of missing data patterns in the ITT sample.

For pattern effects on depressive symptoms, participants with missing data during Pieces 1–3 (Patterns 1–3, respectively) were compared to participants with no missing data during the 26-month follow-up period. Nonsignificant group differences for missing data patterns and for random, fixed, and interaction effects (Pattern × Piece × Group) indicate that missingness did not meaningfully affect the rate of change in depressive symptoms by intervention group. For this reason and because primary missing data comparisons did not differ for SWL, FIML estimation was used to model depressive symptoms and SWL.

**Sample Size**

We had .80 power to detect a Cohen’s $b$ value of .58 for relapse/recurrence (medium effect size) and a hazard ratio (HR) of .36 for time to relapse/recurrence (large effect size). These effect sizes are similar to those observed in previous studies that compared MBCT to TAU. For the mixed-effects model predicting depressive symptoms, we calculated sample size based on the number of observations in the group with the smallest number of observations. Using this conservative approach to calculating sample size, we had .80 power to detect a beta of .16 (small effect size).

**Results**

**Preliminary Analyses**

Figure 1 shows previously reported information on screening, randomization, and attrition. Table 1 shows clinical characteristics of the sample.

**Depressive Relapse/Recurrence and Time to Relapse/Recurrence**

For ITT relapse/recurrence rates, sensitivity analyses were conducted whereby missing values in the MBCT and ACC conditions were imputed based on the observed relapse/recurrence rates in the opposite arm (Proschan et al., 2001). Over the 26-month study period, 1 relapse/recurrence rates in the ITT sample were 47.8% (22/46) for MBCT and 50.0% (23/46) for ACC ($OR = 1, 95\% CI [0.443, 2.24], p = .99$). The difference between 47.8 and 50.0% relapse yields an $b$ value of .043, indicating a small effect size. Relapse/recurrence rates in the PP sample were 47.4% (9/19) for MBCT and 51.9% (14/27) for ACC ($OR = .84, 95\% CI [0.258, 2.71], p = .76$). A Cox regression indicated no difference in time to relapse/recurrence between the two groups—ITT: Wald (3, $n = 92$) = 3.42, $HR = .76, CI [.30, 1.89], p = .55$; and PP: Wald (1, $n = 46$) = 0.32, $HR = .78, CI [.33, 1.86], p = .57$ (see Figure 2). The pattern and significance of results remain unchanged when excluding individuals with two or fewer prior episodes ($n = 5$), who have not benefited from MBCT in prior studies (Teasdale et al., 2000). Effect sizes for PP and ITT analyses from OR and HR models were small.

To examine whether intervention effects for relapse/recurrence rates and time to relapse/recurrence differed for subgroups of participants, we tested each putative moderator in separate ITT regression analyses. 4 No moderation term was statistically significant ($ps > .05$). The interaction between baseline depressive symptoms and intervention group was marginal ($p = .07$). For participants with lower baseline depressive symptoms, MBCT (vs. ACC) was associated with a marginally longer time to relapse/recurrence. For participants with higher baseline symptoms, MBCT (vs. ACC) was associated with a marginally shorter time to relapse/recurrence.

---

1 A final censoring time of 31.4 months was used for survival analyses in order to accommodate data collection from a maximum number of participants. Although follow-up times were slightly longer for MBCT versus ACC, $t(55) = -2.40, p = .02$, results for relapse rates and time to relapse were unchanged when using the same follow-up period (25.7 months) that was used for depressive symptoms. Final follow-up time for depressive symptoms was based on targeted assessment time (8 weeks of training plus 24 months) for both groups.

2 Sample size for per-protocol analysis was restricted to the 46 participants who completed ≥ 4 sessions and who provided follow-up data on relapse/recurrence.

3 Results when including only individuals with ≥ 3 prior episodes of depression ($n=87$): Over the 24-month study period, in the ITT sample, 50.0% (22/44) of the MBCT participants relapsed and 51.2% (22/43) of the ACC participants relapsed. In the PP sample, 50.0% (9/18) of the MBCT participants relapsed, compared with 50.0% (13/25) of the ACC participants. Cox regression indicated no difference in incidence and time to relapse between the two treatment groups; ITT: Wald (3, $n=87$) = 3.61; hazard ratio (HR) = 0.82, $CI[0.34, 1.99], p = .67$; and PP: Wald (1, $n=40$) = 0.23, $HR = .84$, $CI[0.41, 1.72], p = .63$.

4 Only ITT analyses were used to examine moderators because of limited power in PP sample.
recurrence. Effect sizes from moderation analyses were small.

DEPRESSIVE SYMPTOMS AND LIFE SATISFACTION
The final model for depressive symptoms, summarized in Table 2, included random effects of Pieces 1 and 3, fixed effects of group, Pieces 1–3, Piece 1 × Group, and Piece 2 × Group. Analyses indicated a significant overall linear decrease in symptoms during Piece 1 (from pre- to postintervention). This was qualified by a significant Piece 1 × Group interaction, such that the ACC group, compared to MBCT, experienced steeper declines in depressive symptoms. The Piece 2 (from postintervention to 12 months) × Group interaction was also statistically significant, such that the MBCT group, but not the ACC group, experienced a linear decrease in depressive symptoms. The fixed effect of Piece 3 (from 12 to 26 months) was not statistically significant, although there was an upward trend ($p = .07$) in depressive symptoms for both groups (see Figure 3).

The final model for life satisfaction, summarized in Table 2, included random effects of Pieces 1 and 2, fixed effects of group, and Pieces 1–3. Analyses indicated no significant effects of intervention group or Piece × Group interactions. Fixed effects of Pieces 1 and 2 were statistically significant, such that there was a linear increase in life satisfaction from pre- to postintervention and from postintervention to
12 months for both intervention groups. The fixed effect of Piece 3 was not significant, though there was a downward trend ($p = .06$) in life satisfaction for both groups (see Figure 3). Effect sizes for the trajectory of depressive symptoms and life satisfaction over the 26-month follow-up were small. Mixed-effect models comparing depressive symptom and life satisfaction scores at baseline to scores at 26 months indicated that depressive symptoms at 26 months were significantly lower than baseline symptoms, $b = -4.12$, $p = .008$ ($ß = -.55$, large effect size), and there was no interaction with group, $p = .30$. Similarly, life satisfaction at 26 months was significantly higher than baseline satisfaction for both groups, $b = 0.77$, $p = .001$ ($ß = .47$, medium effect size), and there was no interaction with group, $p = .84$.

**Discussion**

To our knowledge, this is the longest follow-up study comparing the effects of MBCT to a structurally
equivalent and validated ACC, which was matched to MBCT on nonspecific components including amount of group contact, treatment-related activity outside of class, interaction with a facilitator, therapeutic allegiance and alliance, emphasis on self-monitoring and behavior change, perceived social support, and expected positive outcomes. Results indicated no differences between MBCT and ACC for relapse/recurrence rates, time to relapse/recurrence, depressive symptoms, or life satisfaction over the 26-month follow-up. Piecewise analyses, which modeled both the original 12-month follow-up period as well as the extended 12- to 26-month follow-up, corroborated the same pattern of results that were reported in the original investigation from baseline to 12 months. Specifically, both groups experienced a significant reduction in depressive symptoms over the 12-month follow-up. The ACC group experienced initial declines in symptoms, which were followed by a gradual increase in symptoms up to the 12-month follow-up, while the MBCT group experienced steady declines in symptoms from postintervention to the 12-month follow-up. Results for the extended follow-up period (12–26 months) indicated that the potentially favorable trajectory of symptomatic improvement in the MBCT versus the ACC group from the end of intervention to the 12-month follow-up was not sustained beyond 12 months. Instead, both the MBCT and ACC group experienced a marginally significant increase in depressive symptoms from the 12- to the 26-month follow-up. However, symptoms in both

![Depressive symptoms (Panel A) and life satisfaction (Panel B)](image-url)

**FIGURE 3** Depressive symptoms (Beck Depression Inventory–II [BDI-II]; Panel A) and life satisfaction (Satisfaction with Life Scale [SWL]; Panel B) in the mindfulness-based cognitive therapy (MBCT) and active control condition (ACC) groups; 0 = baseline (preintervention); Piece 1 = baseline to postintervention; Piece 2 = postintervention to 12 months; Piece 3 = 12–26 months. BDI-II scale range: 0–63; SWL scale range: 1–7.
groups remained significantly lower than baseline at the 26-month assessment. The overall pattern of results for life satisfaction was similar, although slopes of improvement over the 12-month follow-up did not differ between groups. Effect sizes of between-group differences for relapse/recurrence, depressive symptoms, and life satisfaction were all small. Effect sizes for improvements in depressive symptoms and life satisfaction from baseline to the 26-month follow-up were large and medium, respectively.

Confidence in these findings is strengthened by several considerations. First, the two interventions did not differ across four outcomes, thus corroborating the robustness of the present results. Further, all between-group effect sizes were small, suggesting that lack of statistical significance was not due to lack of power. Second, two other studies that have compared MBCT and mindfulness-based stress reduction (MBSR) to the same ACC used in the present study (HEP) have similarly found a lack of group differences on depression outcomes (Eisendrath et al., 2016; MacCoon et al., 2012). This precedence helps to support the veracity of the present study’s results, which generalize only to MBCT and not a broader range of MBIs in the literature. Third, the strong design sensitivity of this trial (e.g., validity/reliability of measures, stratified randomization, and stringent statistical analyses) minimizes the likelihood of Type II error. Finally, support for internal validity of the intervention comes from high therapist adherence and treatment expectancy and credibility ratings (see original investigation for complete details) that were comparable to other MBCT studies (Kuyken et al., 2008; Meadows et al., 2014; Segal et al., 2010). The quality of the delivery of MBCT is additionally supported by the 48% relapse/recurrence rate observed in the MBCT group, which is comparable to at least three other rigorous MBCT trials (Kuyken et al., 2008, 2015; Williams et al., 2014) and supports that MBCT was delivered as intended. In sum, the lack of differences between MBCT and ACC are substantiated by the consistency of small effect sizes across three indicators of depression (relapse rates, time to relapse, depressive symptoms) as well as life satisfaction, corroboration with other study findings that have used the same ACC, strong design sensitivity, and evidence supporting high internal validity.

Moderation analyses for relapse/recurrence outcomes indicated no significant effect modification by age of onset of depression, baseline depressive symptoms, life satisfaction, or ADM use, sex, per-protocol completion, or self-reported practice (ps > .07, all small effect sizes). A marginal interaction between severity of baseline depressive symptoms and intervention group (p = .07) indicated that in individuals with lower baseline depressive symptoms, MBCT versus ACC was associated with a marginally longer time to relapse/recurrence over 26 months, while in individuals with higher baseline symptoms, MBCT versus ACC was associated with a marginally shorter time to relapse/recurrence. This result must be interpreted with caution, however, given that our sample size was minimally powered to detect interaction effects and we did not correct for multiple comparisons. Also, this finding is inconsistent with evidence supporting that greater severity of depressive symptoms at baseline is associated with a more beneficial effect of MBCT compared with other active treatments (including rigorous psychoeducational controls) for relapse/recurrence prevention (Kuyken et al., 2016) and depressive symptom reduction (Chiesa et al., 2015). Replication in future, well-powered trials is needed to follow up on this marginal finding. Collectively, however, results from our moderation analyses add to the developing knowledge about for whom MBCT (vs. other psychoeducational interventions) may be effective.

One important consideration is that although depressive relapse/recurrence rates in this study were comparable to those of other MBCT trials, room for improvement remains given that 50% of participants still experienced a depressive relapse/recurrence. Evidence from this 26-month follow-up study supports the possible utility of continued support or booster sessions beyond the 8-week treatment and indicates the need for such support before 12-months postintervention, when depressive symptoms begin to increase.

Overall, the present results indicate that benefits of MBCT versus ACC for depression outcomes did not emerge beyond a 12-month follow-up and that MBCT is not more effective than an ACC for preventing depressive relapse/recurrence or reducing depressive symptoms and improving life satisfaction over a 26-month follow-up. Epidemiological data and benchmarks from prior depression prevention trials support that both treatments may have been associated with enduring positive outcomes in terms of relapse/recurrence, depressive symptoms, and life satisfaction. For example, relapse/recurrence rates in people with three or more previous episodes are as high as 80% over 2 years in placebo control groups (Kupfer et al., 1992). Further, the 47.8% (MBCT) and the 50% (ACC) relapse/recurrence rates observed in this study are comparable to longer-term relapse rates (e.g., 15 and 24 months) observed in individuals assigned to mADM conditions in prior studies (Kuyken, 2008; Kuyken et al., 2015). Meta-analyses consistently support that mADM treatment reduces the odds of relapse by two thirds compared
with usual care or placebo (Geddes et al., 2017). Additionally, relapse rates in the current investigation were lower than the 60–80% relapse rates observed in TAU groups in the two seminal MBCT trials (Ma & Teasdale, 2004; Teasdale et al., 2000) and one other investigation of relapse prevention with a 2-year follow-up (Bockting et al., 2005). Although more recent MBCT investigations have found lower relapse/recurrence rates in TAU groups (ranging from 33 to 53%; Bondolfi et al., 2010; Williams et al., 2014) than those observed in earlier trials, these lower rates are hypothesized to be driven by the high caliber of mental health care received in the TAU groups in these studies. For example, improvements in depression management since the seminal MBCT studies (due to amended National Institute for Health and Care Excellence guidelines in the United Kingdom) may have yielded lower TAU relapse rates than those found in earlier studies (Williams et al., 2014). Similarly, the high accessibility to mental health care in the Swiss health care system, where psychiatrists rather than general practitioners are the first line of care, may have resulted in a more rigorous TAU group than would be expected in studies conducted in countries with inferior health care systems (Bondolfi et al., 2010). One final consideration in support of the potential efficacy of both interventions tested here is that despite being at high risk for experiencing symptomatic deterioration, depressive symptoms remained lower than baseline levels and did not increase over the 26-month follow-up. Collectively, these considerations support the possibility that both interventions may lead to enduring positive outcomes. However, three-arm studies are needed that compare MBCT versus ACCs versus TAU to rule out time-related effects and to confirm the therapeutic benefit of both interventions.

The potential value of both interventions for long-term well-being is significant because mADM is the most common approach to relapse/recurrence prevention and viable options for nonpharmacological management are needed. Also, there are limited options for group-based preventative treatments for depression, which may have cost, and hence scalability, advantages over individual-based approaches for depression prevention. Finally, results highlight that psychosocial treatments that incorporate some of the specific components of the HEP (e.g., physical activity) may be viable treatment options for individuals who cannot access MBCT, which is not yet widely available.

LIMITATIONS

The present study had three notable limitations. First, our assessments of relapse/recurrence did not allow us to differentiate between these two outcomes. Distinguishing between depressive relapse (the reemergence of depressive symptoms following remission but preceding recovery) and recurrence (the onset of a new episode following recovery) is important for understanding the efficacy and consistency of effects of preventative interventions for depression and for informing trial design and methods for future investigations (Bockting et al., 2015).

Second, attrition rates over the follow-up assessment period were higher than other MBCT trials. Attrition did not vary between groups and data were missing completely at random for all models with the exception of the hazard model for the ITT sample whereby Pattern 1 was entered as a covariate. Thus, analyses were conducted with appropriate rigor, and statistical model assumptions were met. Higher attrition in the present study may be explained by unique demographic characteristics of the study sample that have been associated with lower retention in other clinical trials (Alexander et al., 2017; Ejiogu et al., 2011). For example, the present sample had greater racial/ethnic diversity, lower average socioeconomic status, and lower average age compared with other MBCT studies (Segal et al., 2010; Williams et al., 2014). Thus, greater attrition may be expected due at least in part to potential social and financial disadvantages among these groups (Mein et al., 2012). Relatedly, Caucasian compared with non-Caucasian participants in this trial attended a greater number of sessions ($r = .242$, $p = .02$), which may reflect the need to culturally tailor the MBCT and HEP protocols. Overall, lower adherence in this and at least one other community-based trial of MBCT (Meadows et al., 2014) points to potential challenges with the feasibility and acceptability of the delivery of MBCT for relapse prevention in community-based settings with socio-economically disadvantaged and racially/ethnically diverse participants and in sites away from where the majority of MBCT trials have been conducted (e.g., Western European and Canadian academic medical centers and clinics).

Finally, the sample size for the current investigation was based on available effect sizes in the literature at the start of this trial, which did not include those based on studies that compared MBCT to ACCs. Given effect sizes comparing MBCT to an ACC are likely smaller than those comparing MBCT to TAU, sample sizes needed for studies comparing MBCT to TAU are likely smaller than those needed for studies comparing MBCT to an ACC. This points to a potential issue with power in this study. For example, for our primary outcomes, based on our observed HR for time to
relapse/recurrence (HR = .76), 425 participants per group would be needed to have 80% power to detect group differences at alpha = .05. Based on the difference between relapse/recurrence rates in MBCT versus ACC (Cohen’s $d = 0.43$), a sample size of $>6,000$ participants per group would be needed to have 80% power to detect group differences at alpha = .05. Future studies should balance the practicality of conducting studies that would require these large sample sizes with considerations for the sample size needed to detect the smallest clinically meaningful difference. In sum, our primary null results are unlikely due to power. Further, these results provide estimates of effect sizes for replication studies and for future Stage III–V effectiveness trials of MBCT for depression (Dimidjian & Segal, 2015).

**Conclusion**

We did not find any evidence that the therapeutic components specific to MBCT (e.g., mindfulness and cognitive therapy) are more effective than the therapeutic components specific to the ACC (e.g., nutrition, physical activity/functional movement, and music therapy) over a 26-month follow-up. Nonetheless, across 26 months, individuals in both treatment conditions experienced lower depressive relapse/recurrence than what has been shown in TAU control groups in prior investigations as well as sustained reductions in depressive symptoms and improvements in life satisfaction from baseline. Future studies that include passive control conditions (e.g., TAU) are needed to examine whether both MBCT and HEP, compared to TAU, may provide benefit for individuals with recurrent MDD.

**Ethical Standards and Conflict of Interest**

Informed consent was obtained from all participants in this study. The authors declare no conflict of interest.

**References**


Received: August 7, 2017
Accepted: February 2, 2018
Available online: 8 February 2018